- Home
- INTR vs NAMS Comparison
INTR vs NAMS Comparison
Compare INTR & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INTR | NAMS |
|---|---|---|
| Founded | 1994 | 2019 |
| Country | Brazil | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | INTR | NAMS |
|---|---|---|
| Price | $8.98 | $34.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $7.78 | ★ $46.40 |
| AVG Volume (30 Days) | ★ 2.2M | 907.1K |
| Earning Date | 02-05-2026 | 02-25-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | ★ 51.09 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $1,056,044,206.00 | $35,243,000.00 |
| Revenue This Year | $85.08 | N/A |
| Revenue Next Year | $25.23 | N/A |
| P/E Ratio | $17.20 | ★ N/A |
| Revenue Growth | ★ 34.63 | 4.91 |
| 52 Week Low | $4.12 | $14.06 |
| 52 Week High | $10.22 | $42.00 |
Technical Indicators
Market Signals| Indicator | INTR | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 42.55 |
| Support Level | $8.41 | $32.67 |
| Resistance Level | $8.66 | $35.70 |
| Average True Range (ATR) | 0.22 | 1.50 |
| MACD | 0.10 | -0.10 |
| Stochastic Oscillator | 83.85 | 31.72 |
Price Performance
Historical ComparisonAbout INTR Inter & Co. Inc.
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop. It generates maximum revenue from the Banking & Spending segment which comprises a wide range of banking products and services, such as checking accounts, cards, deposits, loans and advances, and other services, which are available to the clients by means of Inter's mobile application.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.